<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03537625</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH-GT</org_study_id>
    <nct_id>NCT03537625</nct_id>
  </id_info>
  <brief_title>Effects of Green Tea on Body Weight Reduction and Gut Microbiota</brief_title>
  <official_title>Effects of Green Tea and Fermented Green Tea Extract on Obese Adults: a Randomized Double-blind, Placebo-controlled Study Focused on Change of Gut Microbiota and Inflammatory Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amorepacific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators randomly assigned green tea extract, fermented green tea extract, or
      placebo in adult subjects whose BMI was 25-35 kg/m2. Participants were 40 in each group, and
      treatment duration was 12 weeks. Primary outcomes were body weight change and fat mass change
      from baseline to 12 weeks, and secondary outcomes were metabolic parameteres and gut
      microbiota.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After screening obese subjects who met the inclusion and exclusion criteria, the
      investigators randomly assigned the two treatment arms and one placebo arm at 1:1:1 ratio. At
      baseline, anthropometric and biochemical evaluations were conducted including body weight,
      body composition (DXA and Fat CT), lipid profiles, and liver function test. The tablets were
      supplied to each participants under double-blind conditions. The investigators obtained blood
      and stool samples both baseline and final visit at 12 weeks. For improving compliance for
      treatments, the investigators checked diary for lifestyle and drug compliance every 6 week.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2016</start_date>
  <completion_date type="Actual">April 13, 2018</completion_date>
  <primary_completion_date type="Actual">April 13, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>Baseline, and 12 weeks</time_frame>
    <description>Body weight change were calculated using electronic scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body fat</measure>
    <time_frame>Baseline, and 12 weeks</time_frame>
    <description>Total body fat change were calculated using DXA and abdominal fat CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>Baseline, 6 weeks, and 12 weeks</time_frame>
    <description>Waist circumference was measured using standard method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>Baseline, and 12 weeks</time_frame>
    <description>total cholesterol, TG, HDL-C, LDL-C, TG/HDL-C, Apo B/ApoA1, Apo B, Apo A1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>Baseline, and 12 weeks</time_frame>
    <description>hs-CRP, ESR, inflammatory cytokines (TNFa, IL-1Î², IL-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota</measure>
    <time_frame>Baseline, and 12 weeks</time_frame>
    <description>Gut Microbiota composition</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Green tea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Green tea extract 2 gram per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fermented green tea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fermented green tea extract 2 gram per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Green tea</intervention_name>
    <description>We made a dietary supplement from Cammellia sinesis O. Kunze, and made tablets containing extract.</description>
    <arm_group_label>Green tea</arm_group_label>
    <arm_group_label>Fermented green tea</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-60 years

          -  BMI 25-35 kg/m2

          -  Abdominal obesity (Waist circumference): Male &gt;90 cm, Female &gt;85cm

        Exclusion Criteria:

          -  Cardiovascular events within 3 months

          -  uncontrolled hypertension (&gt;160/100 mmHg)

          -  Diabetes mellitus

          -  Dyslipidemia under statin therapy

          -  TSH&lt;0.1 uU/ml or&gt;10 uU/ml

          -  Elevated creatinine level (twice higher than upper normal limit)

          -  Elevated AST/ALT level (three times higher than upper normal limit)

          -  Pregnancy, lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

